BMO maintains Novo Nordisk stock target post FDA nod
BMO Capital Markets affirmed their positive stance on Novo Nordisk (NYSE:NVO) shares, maintaining an Outperform rating and a $105.00 price target. This confirmation followed the U.S. Food and Drug ...
Novo Nordisk shares surge on results of new obesity drug trial
Novo Nordisk announced positive trial results for its next-generation obesity drug, leading to a 7.13% surge in its share ...
Novo Nordisk Stock Jumps on Early Stage Weight-Loss Drug Trial Results
Novo Nordisk's U.S.-listed shares are surging 9% Friday morning after the Danish drugmaker reported early stage results for ...
Novo Nordisk next-gen shot shows 22% weight loss in early results
One of Novo Nordisk's next-generation obesity shots to follow up on the success of Wegovy helped patients lose 22% of their ...
Ozempic maker's stock surges. A trial of a new Novo Nordisk drug shows promise.
Novo Nordisk said a Phase 1b/2a clinical trial of amycretin, which activates both the GLP-1 and amylin receptors to help manage blood sugar and weight, achieved weight loss of 22% on a 20 milligram ...
Novo Nordisk Shares Surge on New Obesity Drug Results — Update
The trial tested amycretin in its injectable form, but Novo Nordisk is also separately developing the drug in pill form. Investors cheered an early trial of the pill early last year that showed weight ...
FiercePharma12d
Novo Nordisk touts 'superior' weight loss results in study of high-dose Wegovy
In the ongoing quest to expand semaglutide’s clinical pedigree and cement the GLP-1's market position, Novo Nordisk is ...
Novo Nordisk: STEP UP Trial Achieves Primary Endpoint - Quick Facts
Novo Nordisk (NVO) reported headline results from STEP UP, a phase 3b trial in the global STEP programme. The trial achieved primary ...
99.co14d
Novo Place
Novo Place EC launch sales: 286 out of its 504 units (57%) were sold on the first day of launch on November 16, 2024. The average price for units sold was S$1,654 psf, with starting prices as low as ...
Insider Monkey15d
Jim Cramer on Novo Nordisk A/S (NVO): ‘That’s Denmark’s Jugular’
In this article, we are going to take a look at where Novo Nordisk A/S (NYSE:NVO) stands against the other stocks Jim Cramer recently discussed. In a recent episode of CNBC’s Squawk On The ...
kino21d
Nordisk Film Biografer Næstved
Luksussæder til de store filmoplevelser og med plads til hele familien Masser af parkeringspladser lige ved biografen. Gratis parkering op til 4 timer ved samtidig besøg i biografen. Biografen ligger ...
DR DK25d
Kalundborgs lokalliv i opråb: Novo Nordisk sluger arbejdskraften
Her annoncerede den danske medicinalgigant Novo Nordisk nemlig, at den ville udbygge sin fabrik i byen for svimlende 42 milliarder kroner. - Det er måske den største investering nogensinde i dansk ...